Search research articles
Contact Us
Filters
Showing results (51-60 of 418) with videos related to
Page
of 42
Sort By:
Expert Review of Anticancer Therapy
|
October 15, 2010
Does axitinib (AG-01376) have a future role in metastatic renal cell carcinoma and other malignancies?
Robert Goldstein, Lisa Pickering, James Larkin
Irish Journal of Medical Science
|
September 3, 2021
Diagnostic coding of chronic physical conditions in Irish general practice
Ivana Pericin, James Larkin, Claire Collins
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|
May 21, 2015
Challenging the treatment paradigm for advanced renal cell carcinoma: a review of systemic and localized therapies
Axel Bex, James Larkin, Martin Voss
The EPMA Journal
|
June 29, 2012
Delivering preventive, predictive and personalised cancer medicine for renal cell carcinoma: the challenge of tumour heterogeneity
Rosalie Fisher, James Larkin, Charles Swanton
Seminars in Cancer Biology
|
April 5, 2021
Predictive biomarkers for response to immune checkpoint inhibition
Benjamin Shum, James Larkin, Samra Turajlic
Melanoma Management
|
September 8, 2018
Anti-PD-1 monotherapy versus anti-PD1 plus anti-CTLA4 in advanced melanoma: how do we decide?
Lewis Au, Aine O'Reilly, James Larkin
Journal of Neurology, Neurosurgery, and Psychiatry
|
July 30, 2025
Neurological immune-related adverse events with immune checkpoint inhibitors: collaboration is key
Anadil Javaid, Tobias Peres, James Larkin
Health Policy (Amsterdam, Netherlands)
|
August 25, 2021
Payments reported by the pharmaceutical industry in Ireland from 2015 to 2019: An observational study
Frank Moriarty, James Larkin, Tom Fahey
Cancer Immunology, Immunotherapy : CII
|
May 20, 2016
Determining predictive factors for immune checkpoint inhibitor toxicity: Response to Letter to the Editors "A case report of insulin-dependent diabetes as immune-related toxicity of pembrolizumab: presentation, management and outcome"
Lavinia Spain, James Larkin, Juan Martin-Liberal
The Lancet. Oncology
|
September 2, 2022
Hitting the sweet spot: optimal use of corticosteroids for immune checkpoint inhibitor side-effects
Andreas M Schmitt, Lavinia Spain, James Larkin
Page
of 42
Search research articles
Search
Showing results (51-60 of 418) with videos related to
Sort By:
Page
of 42
Expert Review of Anticancer Therapy
|
October 15, 2010
Does axitinib (AG-01376) have a future role in metastatic renal cell carcinoma and other malignancies?
Robert Goldstein, Lisa Pickering, James Larkin
Irish Journal of Medical Science
|
September 3, 2021
Diagnostic coding of chronic physical conditions in Irish general practice
Ivana Pericin, James Larkin, Claire Collins
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|
May 21, 2015
Challenging the treatment paradigm for advanced renal cell carcinoma: a review of systemic and localized therapies
Axel Bex, James Larkin, Martin Voss
The EPMA Journal
|
June 29, 2012
Delivering preventive, predictive and personalised cancer medicine for renal cell carcinoma: the challenge of tumour heterogeneity
Rosalie Fisher, James Larkin, Charles Swanton
Seminars in Cancer Biology
|
April 5, 2021
Predictive biomarkers for response to immune checkpoint inhibition
Benjamin Shum, James Larkin, Samra Turajlic
Melanoma Management
|
September 8, 2018
Anti-PD-1 monotherapy versus anti-PD1 plus anti-CTLA4 in advanced melanoma: how do we decide?
Lewis Au, Aine O'Reilly, James Larkin
Journal of Neurology, Neurosurgery, and Psychiatry
|
July 30, 2025
Neurological immune-related adverse events with immune checkpoint inhibitors: collaboration is key
Anadil Javaid, Tobias Peres, James Larkin
Health Policy (Amsterdam, Netherlands)
|
August 25, 2021
Payments reported by the pharmaceutical industry in Ireland from 2015 to 2019: An observational study
Frank Moriarty, James Larkin, Tom Fahey
Cancer Immunology, Immunotherapy : CII
|
May 20, 2016
Determining predictive factors for immune checkpoint inhibitor toxicity: Response to Letter to the Editors "A case report of insulin-dependent diabetes as immune-related toxicity of pembrolizumab: presentation, management and outcome"
Lavinia Spain, James Larkin, Juan Martin-Liberal
The Lancet. Oncology
|
September 2, 2022
Hitting the sweet spot: optimal use of corticosteroids for immune checkpoint inhibitor side-effects
Andreas M Schmitt, Lavinia Spain, James Larkin
Page
of 42